The offices of the Yangtze River Pharmaceutical Group [Photo/WeChat ID: tzfabu]
Founded in 1971, the Yangtze River Pharmaceutical Group, or YRPG, is a Chinese pharmaceutical group listed by the Ministry of Science and Technology as one of the first Innovative Enterprises of China.
In 2021, with an annual revenue of 78.55 billion yuan ($11.78 billion), the group ranked 116th in the list of Top 500 Chinese private enterprises and 66th in the list of Top 500 Chinese private manufacturers.
Headquartered in Taizhou city, in East China's Jiangsu province, YRPG owns over 20 subsidiaries with over 16,000 employees in total – located in Beijing, Shanghai, Guangzhou in Guangdong province, Chengdu in Sichuan province, Nanjing, Suzhou, Taizhou and Changzhou in Jiangsu province.
YRPG owns four national innovation R&D platforms. It has won three Second Class Prizes in the State Science and Technology Advancement Awards. Five of its international standards for Chinese medicinal materials have been entered into the European Pharmacopoeia reference work for the quality control of medicines on the continent.
YRPG is designated as a Practical Training Base by the National Institute of Food and Drug Control and the Jiangsu Food and Drug Administration.
YRPG was also honored with the Nomination of China Quality Award, the Global Performance Excellence Award (World Class), the Asia Quality Innovation Award and as a National Enterprise for "Keeping Promises & Honoring Contracts" and as a National Civilized Unit.
Since 2005, YRPG has won the most first prizes in QC achievements in the China Pharmaceutical Industry for 17 consecutive years. From 2015 to 2020, YRPG won 24 Gold Awards from the International Convention on Quality Control Circles, or ICQCC.